Form 8-K - Current report:
SEC Accession No. 0001437749-23-006915
Filing Date
2023-03-16
Accepted
2023-03-16 16:31:16
Documents
13
Period of Report
2023-03-10
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20230316_8k.htm   iXBRL 8-K 31858
  Complete submission text file 0001437749-23-006915.txt   183232

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA navb-20230310.xsd EX-101.SCH 4035
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20230310_def.xml EX-101.DEF 13875
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20230310_lab.xml EX-101.LAB 18171
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20230310_pre.xml EX-101.PRE 13897
7 EXTRACTED XBRL INSTANCE DOCUMENT navb20230316_8k_htm.xml XML 4293
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

EIN.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 23739261
SIC: 2835 In Vitro & In Vivo Diagnostic Substances